No Data
No Data
Beigene (06160) class 1 new drug BGB-43395 tablet approved for clinical use in breast cancer and other solid tumors.
On August 22nd, the official website of China National Medical Products Administration (NMPA) Drug Evaluation Center (CDE) announced that Beigene (06160) has received clinical approval for the first class of new drug BGB-43395 tablets. It is intended to be used for monotherapy or in combination with fluorouracil and vinorelbine or other drugs for the treatment of advanced or metastatic HR+/HER2- breast cancer and other solid tumors.
HKEX abnormal movement| BeiGene (06160) rose nearly 3% in the morning, and many innovative drug companies welcomed their mid-year reports with joy. The company's BTK drug market share continues to expand in the United States.
Beigene (06160) rose nearly 3% in the morning. As of press time, it rose 2.82% to HKD 120.5, with a turnover of HKD 90.0317 million.
BeiGene Is Maintained at Overweight by JP Morgan
BeiGene Analyst Ratings
J.P. Morgan Maintains BeiGene(BGNE.US) With Buy Rating, Raises Target Price to $200
Express News | Beigene : JP Morgan Raises Target Price to $200 From $194